Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Short-Term Debt: ¥1,005 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600513 Jiangsu Lianhuan Pharmaceutical Co Ltd SHSE:600513
67 GF Score
Price ¥15.65
GF Value ¥15.58
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Jiangsu Lianhuan Pharmaceutical Co Short-Term Debt?

Jiangsu Lianhuan Pharmaceutical Co SHSE:600513 -1.94% 67 Short-Term Debt is ¥1,005 Mil as of Jun. 2026. GuruFocus rates SHSE:600513 with a GF Score™ of 67/100 and a GF Value™ of ¥15.58 (Fairly Valued). The stock has 9 warning signs investors should review.

Jiangsu Lianhuan Pharmaceutical Co's Short-Term Debt for the quarter that ended in Jun. 2026 was ¥1,005 Mil.

Jiangsu Lianhuan Pharmaceutical Co's quarterly Short-Term Debt increased from Dec. 2025 (¥959 Mil) to Mar. 2026 (¥1,036 Mil) but then declined from Mar. 2026 (¥1,036 Mil) to Jun. 2026 (¥1,005 Mil).

Jiangsu Lianhuan Pharmaceutical Co's annual Short-Term Debt increased from Dec. 2023 (¥592 Mil) to Dec. 2024 (¥698 Mil) and increased from Dec. 2024 (¥698 Mil) to Dec. 2025 (¥959 Mil).

Jiangsu Lianhuan Pharmaceutical Co Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Jiangsu Lianhuan Pharmaceutical Co Short-Term Debt Related Terms

Jiangsu Lianhuan Pharmaceutical Co Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Jiangsu Lianhuan Pharmaceutical Co's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Lianhuan Pharmaceutical Co Short-Term Debt Chart

Jiangsu Lianhuan Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 454.07 538.30 591.76 697.72 958.59

Jiangsu Lianhuan Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 897.06 935.15 958.59 1,035.63 1,005.10
SHSE:600513
67GF Score
Jiangsu Lianhuan Pharmaceutical Co Ltd SHSE:600513
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ¥1,005 Mil mean?
Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) has a Short-Term Debt of ¥1,005 Mil as of Jun. 2026.
Is Jiangsu Lianhuan Pharmaceutical Co's Short-Term Debt too high?
Jiangsu Lianhuan Pharmaceutical Co's current Short-Term Debt is ¥1,005 Mil. Overall, Jiangsu Lianhuan Pharmaceutical Co has a GF Score™ of 67/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Lianhuan Pharmaceutical Co's Short-Term Debt compare to ZTS?
Jiangsu Lianhuan Pharmaceutical Co's Short-Term Debt of ¥1,005 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Jiangsu Lianhuan Pharmaceutical Co's current Short-Term Debt is ¥1,005 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Lianhuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.58, compared to a current price of ¥15.65 — trading 0.4% above its estimated fair value. The current Short-Term Debt is ¥1,005 Mil. Jiangsu Lianhuan Pharmaceutical Co's overall GF Score™ is 67/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513), the current Short-Term Debt is ¥1,005 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥15.65 is trading 0.4% above its estimated GF Value™ of ¥15.58. GuruFocus considers Jiangsu Lianhuan Pharmaceutical Co to be Fairly Valued.

Key valuation signals for SHSE:600513:

  • Short-Term Debt: ¥1,005 Mil
  • GF Value™: ¥15.58 vs. price of ¥15.65 (0.4% above fair value)
  • GF Score™: 67/100 with 9 warning signs

No single metric tells the full story. See the SHSE:600513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Jiangsu Lianhuan Pharmaceutical Co Business Description

Address No. 9, Jiankang 1st Road, Yangzhou Bio-Health Industry Park, Jiangsu Province, Yangzhou, Jiangsu, CHN, 225127
Jiangsu Lianhuan Pharmaceutical Co Ltd is engaged in producing benign prostatic hyperplasia, allergy and cardiovascular drugs. In the field of pharmaceutical manufacturing, the company's main products include several series such as urinary system drugs, antihistamines, cardiovascular drugs, steroid hormones, antibiotics, etc., covering chemical raw materials and injections, solid preparations and various drug dosage forms, including the national first-class new drug Apelite Tablets (Chuanliu).
67GF Score

Get the complete analysis for SHSE:600513

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥15.65
Price
¥15.58
GF Value